Vaccine:预防啮齿类动物的埃博拉病毒长效疫苗问世

2015-03-27 佚名 不详

近日,来自英国普利茅斯大学的研究人员在国际学术期刊Vaccine发文宣称他们开发出针对埃博拉病毒的长效疫苗,应用该疫苗或可降低野生非洲猿的埃博拉病毒感染,对非洲埃博拉病毒的预防治疗具有重要意义。   非洲猿是埃博拉病毒向人类传播的一个主要传染源。因此预防非洲猿发生埃博拉病毒感染能够降低埃博拉病毒在非洲人口中爆发的可能性。埃博拉病毒感染对非洲猿同样具有致死性,同时也是威胁这些野

近日,来自英国普利茅斯大学的研究人员在国际学术期刊Vaccine发文宣称他们开发出针对埃博拉病毒的长效疫苗,应用该疫苗或可降低野生非洲猿的埃博拉病毒感染,对非洲埃博拉病毒的预防治疗具有重要意义。
 
非洲猿是埃博拉病毒向人类传播的一个主要传染源。因此预防非洲猿发生埃博拉病毒感染能够降低埃博拉病毒在非洲人口中爆发的可能性。埃博拉病毒感染对非洲猿同样具有致死性,同时也是威胁这些野生种群生存的主要危险因素之一。针对埃博拉病毒的长效疫苗开发为稳定这些濒危猿类的种群数量以及保护人类免受埃博拉病毒感染提供了希望。
 
研究人员在CMV病毒基础上开发了针对埃博拉病毒的长效疫苗。改造后的CMV病毒在去除了其免疫原性和种属特异性后,也能够比较容易得在个体之间进行传播,并且这一过程不会受到宿主CMV免疫的影响。因此基于CMV病毒这一特性开发的埃博拉病毒疫苗不需要直接接种便可在非洲猿身上诱导具有机体保护性的埃博拉病毒特异性免疫应答,并能够在野生猿个体之间广泛传播。应用该种疫苗,宿主产生的接种后免疫应答最少可维持接近四个月,长效免疫对于这种传播性疫苗方法取得最终成功具有至关重要的作用。
 
目前,研究人员正加紧研发可应用于人类的长效埃博拉病毒疫苗,若能获得该疫苗,对于非洲埃博拉病毒控制将具有非常重大的意义。

原始出处:
Wong G, Audet J, Fernando L, Fausther-Bovendo H, Alimonti JB, Kobinger GP, Qiu X.Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine. 2014 Sep 29;32(43):5722-9

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773486, encodeId=60bc1e73486ad, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Sep 30 21:16:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650331, encodeId=cc90165033154, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Jun 09 16:16:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296438, encodeId=1ebb1296438f8, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sun Mar 29 00:16:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325017, encodeId=16c8132501e58, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 29 00:16:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19006, encodeId=445d1900630, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 28 07:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=)]
    2015-09-30 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773486, encodeId=60bc1e73486ad, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Sep 30 21:16:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650331, encodeId=cc90165033154, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Jun 09 16:16:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296438, encodeId=1ebb1296438f8, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sun Mar 29 00:16:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325017, encodeId=16c8132501e58, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 29 00:16:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19006, encodeId=445d1900630, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 28 07:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773486, encodeId=60bc1e73486ad, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Sep 30 21:16:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650331, encodeId=cc90165033154, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Jun 09 16:16:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296438, encodeId=1ebb1296438f8, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sun Mar 29 00:16:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325017, encodeId=16c8132501e58, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 29 00:16:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19006, encodeId=445d1900630, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 28 07:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773486, encodeId=60bc1e73486ad, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Sep 30 21:16:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650331, encodeId=cc90165033154, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Jun 09 16:16:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296438, encodeId=1ebb1296438f8, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sun Mar 29 00:16:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325017, encodeId=16c8132501e58, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 29 00:16:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19006, encodeId=445d1900630, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 28 07:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1773486, encodeId=60bc1e73486ad, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Wed Sep 30 21:16:00 CST 2015, time=2015-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1650331, encodeId=cc90165033154, content=<a href='/topic/show?id=9e424155935' target=_blank style='color:#2F92EE;'>#埃博拉病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41559, encryptionId=9e424155935, topicName=埃博拉病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=639b24003788, createdName=tcm107hq, createdTime=Tue Jun 09 16:16:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296438, encodeId=1ebb1296438f8, content=<a href='/topic/show?id=76f941560d7' target=_blank style='color:#2F92EE;'>#埃博拉病毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41560, encryptionId=76f941560d7, topicName=埃博拉病毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85aa264, createdName=redcrab, createdTime=Sun Mar 29 00:16:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325017, encodeId=16c8132501e58, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Mar 29 00:16:00 CST 2015, time=2015-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19006, encodeId=445d1900630, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Sat Mar 28 07:51:00 CST 2015, time=2015-03-28, status=1, ipAttribution=)]
    2015-03-28 zhouanxiu

    厉害

    0

相关资讯

埃博拉抗体药物将量产?

据日本《读卖新闻》3月2日报道,日本田边三菱制药公司公布称,将会与美国政府携手研究埃博拉出血热病毒抗体。据悉,埃博拉对抗措施是美国国家级项目,而美国政府也将负担费用,进行量产药物的有关技术开发研究。 美国研究人员正在开发中的新药“ZMapp”虽还未认证,但却是埃博拉出血热治疗药物的有力候补之一。而田边三菱制药的子公司“Medicago”则会就如何量产药物中所含抗体进行研究。“Medicago

默克&NewLink 埃博拉疫苗启动四期临床试验

世卫组织WHO 5日宣布默克 -NewLink 共同研发的埃博拉疫苗将于3月7日在几内亚开始四期临床试验。 尽管西非的埃博拉疫情有所控制,但全球健康组织的权威WHO依然相当重视埃博拉病毒相关药物的研发,继默克埃博拉疫苗之后,GSK的疫苗也即将进行四期临床试验。“一定要确保疫苗供应充足。”WHO官员说道。 据统计,自2013年12月埃博拉疫情大爆发以来,已经有23,900名确诊或疑似病例,其

一个赴非抗埃医生生前发给女儿的微信

一个家庭的群由于爸爸在非洲,妈妈在四川,女儿在上海,为了交流方便,女儿专门建了一个家庭微信群他第一次点赞“爸爸,等你平安归来,女儿带你去海钓,好不好?”刚学会用微信的爸爸在下面调皮地点了个赞我们为他点赞今年1月,爸爸在执行援外医疗任务时突发大面积心肌梗塞,经全力抢救无效,不幸逝世,年仅50岁2014年2月以来,西非地区爆发了大规模的埃博拉出血热疫情,中国政府和军队第一时间向西非各国派遣医疗专家

Lancet:中国江苏泰州新型埃博拉疫苗安全性和免疫原性的研究

背景 到现在为止,所有测试的埃博拉病毒疫苗都是根据1976年病扎伊尔爆发的毒株,我们的目的是评估一个新的重组腺病毒5型的基于矢量的埃博拉疫苗的2014年流行的糖蛋白菌株安全性和免疫原性表达。 方法我们在中国江苏省泰州县的一个站点做的随机,双盲,安慰剂对照,第一阶段的临床试验。健康成人(年龄18-60岁)依次登记和随机分配(2:1),由计算机生成的随机化块(6的块大小),接受安慰剂,低剂量的腺病毒

美国首例感染埃博拉护士状告医院

首位在美国境内感染埃博拉病毒的达拉斯亚裔女护士范妮娜(NinaPham),3月2日向法院递交一纸诉状,将自己任职医院的母公司告上法庭,认为院方在培训和保护前线医护人员上没有尽到责任,自己深受感染埃博拉的后遗症影响,要求得到经济赔偿。康复后的妮娜·范在新闻发布会上讲述自己的经历现年26岁的范妮娜,是越南裔美国人,此前在达拉斯得州卫生长老会医院担任护士。去年10月,美国本土确诊的首例埃博拉病毒携带者、

“感动中国”特别致敬:抗击埃博拉援非医疗队

感动中国2014年度人物颁奖特别致敬抗击埃博拉病毒中国援非医疗队。来自央视微博 为抗击埃博拉,重庆的医疗队也做了不少奉献。来自央视微博 2月27日晚,《感动中国2014年度人物颁奖盛典》在央视播出,在接近尾声时,现场举行了一个隆重的特别致敬环节,致敬的对象,就是抗击埃博拉病毒中国援非医疗队。 现场,当屏幕上播放完近2分钟关于中国援非医疗队的工作情况后和对治愈者的采访视频后,主持人宣布